Search
Professor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read moreJosé Carreras Award handed out at the 17th Congress of EHA
He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.
Read moreInternational Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion- dependent children identified each year around the world.
Read moreAcute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab
The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.
Read moreHow malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack
T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.
Read moreReduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
Read moreEMA Issues Call for Expressions of Interest for Drug Safety Studies
The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.
Read moreWould you sell Peripheral Blood derived Stem Cells?
There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.
Read moreEHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read moreReport "Haematology and the next European Decade"
EHA and the European Cancer Patient Coalition co-hosted a meeting at the European Parliament in Brussels on August 30-31, 2011. The two-day conference was attended by doctors, researchers, parliamentarians, patient advocates and Commission officials.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- »